1
|
Rojas-Holguín A, Fondevila-Campo C, Sanjuanbenito A, Fabregat-Prous J, Secanella-Medayo L, Rotellar-Sastre F, Pardo-Sánchez F, Prieto-Calvo M, Marín-Ortega H, Sánchez-Cabús S, Diez-Valladares L, Alonso-Casado Ó, González-Serrano C, Rodríguez-Sanjuan JC, García-Plaza G, Jaén-Torrejimeno I, Suárez-Muñoz MÁ, Becerra-Massare A, Rio PSD, Pando E, López-Andújar R, Muñoz-Forner E, Rodriguez-López M, Pereira F, Serrablo-Requejo A, Turrión VS, Garrido MJ, Burdío F, Martín-Pérez E, Estevan-Estevan R, López-Guerra D, Castell-Gómez J, Salinas-Gómez J, López-Baena JÁ, López-Ben S, Solar-García L, Pérez-Alonso AJ, Martínez-Insfran LA, Blas JL, Cornejo M, Gutierrez-Calvo A, Pozo CDD, Ochando-Cerdan F, Muñoz-Bellvís L, Rebollar-Saenz J, Sánchez B, Jover JM, Gómez-Bravo MÁ, Ramia JM, Blanco-Fernández G. Repeated pancreatic resection for pancreatic metastases from renal cell Carcinoma: A Spanish multicenter study (PANMEKID). Surg Oncol 2024; 52:102039. [PMID: 38301449 DOI: 10.1016/j.suronc.2024.102039] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/12/2023] [Accepted: 01/20/2024] [Indexed: 02/03/2024]
Abstract
BACKGROUND AND OBJECTIVES Recurrent isolated pancreatic metastasis from Renal Cell Carcinoma (RCC) after pancreatic resection is rare. The purpose of our study is to describe a series of cases of relapse of pancreatic metastasis from renal cancer in the pancreatic remnant and its surgical treatment with a repeated pancreatic resection, and to analyse the results of both overall and disease-free survival. METHODS Multicenter retrospective study of patients undergoing pancreatic resection for RCC pancreatic metastases, from January 2010 to May 2020. Patients were grouped into two groups depending on whether they received a single pancreatic resection (SPS) or iterative pancreatic resection. Data on short and long-term outcome after pancreatic resection were collected. RESULTS The study included 131 pancreatic resections performed in 116 patients. Thus, iterative pancreatic surgery (IPS) was performed in 15 patients. The mean length of time between the first pancreatic surgery and the second was 48.9 months (95 % CI: 22.2-56.9). There were no differences in the rate of postoperative complications. The DFS rates at 1, 3 and 5 years were 86 %, 78 % and 78 % vs 75 %, 50 % and 37 % in the IPS and SPS group respectively (p = 0.179). OS rates at 1, 3, 5 and 7 years were 100 %, 100 %, 100 % and 75 % in the IPS group vs 95 %, 85 %, 80 % and 68 % in the SPS group (p = 0.895). CONCLUSION Repeated pancreatic resection in case of relapse of pancreatic metastasis of RCC in the pancreatic remnant is justified, since it achieves OS results similar to those obtained after the first resection.
Collapse
Affiliation(s)
- Adela Rojas-Holguín
- Universidad de Extremadura, Departamento de Terapeútica Médico Quirúrgica, Facultad de Medicina y Ciencias de la Salud, Badajoz, Spain; Department of HBP Surgery and Liver Transplantation, Hospital Universitario de Badajoz, Badajoz, Spain
| | - Constantino Fondevila-Campo
- Department of Surgery, Hospital Clinic, Barcelona, Spain; Department of Surgery, Hospital Universitario La Paz, Madrid, Spain
| | | | - Joan Fabregat-Prous
- Department of Surgery, Hospital Universitario de Bellvitge, Hospitalet de Llobregat, Spain
| | - Luís Secanella-Medayo
- Department of Surgery, Hospital Universitario de Bellvitge, Hospitalet de Llobregat, Spain
| | | | | | | | - Héctor Marín-Ortega
- Department of Surgery, Hospital Clínico Universitario San Carlos, Madrid, Spain
| | | | | | | | | | | | - Gabriel García-Plaza
- Department of Surgery, Hospital Insular de Gran Canaria, Las Palmas de Gran Canaria, Spain
| | - Isabel Jaén-Torrejimeno
- Department of HBP Surgery and Liver Transplantation, Hospital Universitario de Badajoz, Badajoz, Spain
| | | | | | | | - Elizabeth Pando
- Department of Hepato-pancreato-biliary and Transplant Surgery, Hospital Universitario Vall d'Hebron, Barcelona, Spain
| | - Rafael López-Andújar
- CIBERehd, Instituto de Salud Carlos III, Madrid, Spain; Hepatology, HBP Surgery and Transplants, IIS La Fe, Hospital La Fe, Valencia, Spain
| | - Elena Muñoz-Forner
- Department of Surgery, Hospital Clínico Universitario de Valencia, Valencia, Spain
| | - Mario Rodriguez-López
- Department of Surgery, Hospital Clínico Universitario de Valladolid, Valladolid, Spain
| | - Fernando Pereira
- Department of Surgery, Hospital Universitario de Fuenlabrada, Fuenlabrada, Madrid, Spain
| | | | - Víctor Sánchez Turrión
- Department of Surgery, Hospital Universitario Puerta de Hierro, Majadahonda, Madrid, Spain
| | - Manuel Jiménez Garrido
- Department of Surgery, Hospital Universitario Puerta de Hierro, Majadahonda, Madrid, Spain
| | | | - Elena Martín-Pérez
- Department of Surgery, Hospital Universitario de La Princesa, Madrid, Spain
| | | | - Diego López-Guerra
- Universidad de Extremadura, Departamento de Terapeútica Médico Quirúrgica, Facultad de Medicina y Ciencias de la Salud, Badajoz, Spain; Department of HBP Surgery and Liver Transplantation, Hospital Universitario de Badajoz, Badajoz, Spain
| | | | | | | | - Santiago López-Ben
- Department of Surgery, Hospital Universitari Dr Josep Trueta, Girona, Spain
| | - Lorena Solar-García
- Department of Surgery, Hospital Universitario Central de Asturias, Oviedo, Spain
| | - Alejandro J Pérez-Alonso
- Department of Surgery, Hospital Universitario Virgen de las Nieves, Granada, Spain; Department of Surgery, Complejo Hospitalario de Jaén, Jaén, Spain
| | | | - Juan Luis Blas
- Department of Surgery, Hospital Royo Villanova, Zaragoza, Spain
| | - Marian Cornejo
- Department of Surgery, Hospital Marina Baixa, Villajoyosa, Alicante, Spain
| | - Alberto Gutierrez-Calvo
- Department of Surgery Hospital Universitario Principe de Asturias. Alcalá de Henares, Madrid, Spain
| | | | | | - Luis Muñoz-Bellvís
- Department of Surgery, Complejo Asistencial Universitario de Salamanca, Salamanca, Spain
| | | | - Belinda Sánchez
- Department of Surgery, Hospital Regional de Málaga, Málaga, Spain
| | - José María Jover
- Department of Surgery, Hospital Universitario de Getafe, Getafe, Madrid, Spain
| | | | - José M Ramia
- Hepatology, HBP Surgery and Transplants, IIS La Fe, Hospital La Fe, Valencia, Spain; Department of Surgery, Hospital General Universitario de Alicante, Alicante, Spain
| | - Gerardo Blanco-Fernández
- Universidad de Extremadura, Departamento de Terapeútica Médico Quirúrgica, Facultad de Medicina y Ciencias de la Salud, Badajoz, Spain; Department of HBP Surgery and Liver Transplantation, Hospital Universitario de Badajoz, Badajoz, Spain.
| |
Collapse
|
2
|
Aparicio-López D, Palomares-Cano A, Hörndler-Algarate C, Serrablo-Requejo A, Serradilla-Martín M. Mucinous cystic liver neoplasm with invasive component and sarcomatous differentiation. Acta Chir Belg 2023; 123:577-580. [PMID: 35647933 DOI: 10.1080/00015458.2022.2082061] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/28/2021] [Accepted: 05/20/2022] [Indexed: 11/01/2022]
Abstract
BACKGROUND Hepatobiliary mucinous cystic neoplasms (MCN) harbor an invasive carcinoma in 16% of the cases, mainly tubular type, but occasionally sarcomatoid or undifferentiated, these entities being frankly rare. METHODS We present the case of a liver MCN with an invasive component and sarcomatous degeneration. RESULTS The patient was treated surgically with subsequent adjuvant chemotherapy (capecitabine), presenting tumor progression after three months with peritoneal carcinomatosis and liver recurrence. The patient died due to liver failure 4 months after surgery. CONCLUSION MCN with an invasive component and sarcomatous degeneration are very rare, present advanced stages, show aggressive behavior, and have a poor prognosis.
Collapse
Affiliation(s)
| | - Ana Palomares-Cano
- Department of Surgery, Miguel Servet University Hospital, Zaragoza, Spain
| | | | | | - Mario Serradilla-Martín
- Instituto de Investigación Sanitaria Aragón, Department of Surgery, Miguel Servet University Hospital, Zaragoza, Spain
| |
Collapse
|
3
|
Rodríguez-Hernández A, Navarro-Villarán E, González R, Pereira S, Soriano-De Castro LB, Sarrias-Giménez A, Barrera-Pulido L, Álamo-Martínez JM, Serrablo-Requejo A, Blanco-Fernández G, Nogales-Muñoz A, Gila-Bohórquez A, Pacheco D, Torres-Nieto MA, Serrano-Díaz-Canedo J, Suárez-Artacho G, Bernal-Bellido C, Marín-Gómez LM, Barcena JA, Gómez-Bravo MA, Padilla CA, Padillo FJ, Muntané J. Corrigendum to 'Regulation of cell death receptor S-nitrosylation and apoptotic signaling by Sorafenib in hepatoblastoma cells'[Redox Biol 6(2015):174-182]. Redox Biol 2023:102744. [PMID: 37246098 DOI: 10.1016/j.redox.2023.102744] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 05/30/2023] Open
Affiliation(s)
- A Rodríguez-Hernández
- Institute of Biomedicine of Seville (IBiS), Hospital Universitario "Virgen del Rocío"/CSIC/Universidad de Sevilla, Av. Manuel Siurot s/n, 41013, Sevilla, Spain
| | - E Navarro-Villarán
- Institute of Biomedicine of Seville (IBiS), Hospital Universitario "Virgen del Rocío"/CSIC/Universidad de Sevilla, Av. Manuel Siurot s/n, 41013, Sevilla, Spain
| | - R González
- Department of Biochemistry and Molecular Biology, University of Cordoba, Instituto Maimónides de Investigación Biomédica de Córdoba (IMIBIC), 14071, Córdoba, Spain
| | - S Pereira
- Institute of Biomedicine of Seville (IBiS), Hospital Universitario "Virgen del Rocío"/CSIC/Universidad de Sevilla, Av. Manuel Siurot s/n, 41013, Sevilla, Spain
| | - L B Soriano-De Castro
- Institute of Biomedicine of Seville (IBiS), Hospital Universitario "Virgen del Rocío"/CSIC/Universidad de Sevilla, Av. Manuel Siurot s/n, 41013, Sevilla, Spain
| | - A Sarrias-Giménez
- Institute of Biomedicine of Seville (IBiS), Hospital Universitario "Virgen del Rocío"/CSIC/Universidad de Sevilla, Av. Manuel Siurot s/n, 41013, Sevilla, Spain
| | - L Barrera-Pulido
- Department of General Surgery, Hospital Universitario "Virgen del Rocío"-"Virgen Macarena"/Instituto de Biomedicina de Sevilla (IBiS)/CSIC/Universidad de Sevilla, Sevilla, Spain
| | - J M Álamo-Martínez
- Department of General Surgery, Hospital Universitario "Virgen del Rocío"-"Virgen Macarena"/Instituto de Biomedicina de Sevilla (IBiS)/CSIC/Universidad de Sevilla, Sevilla, Spain; CENTRO DE INVESTIGACIÓN BIOMÉDICA EN RED de Enfermedades Hepáticas y Digestivas (CIBERehd), Spain
| | - A Serrablo-Requejo
- Hepato-Biliary Surgery Unit, Hospital Universitario "Miguel Servet", Zaragoza, Spain
| | - G Blanco-Fernández
- Hepato-Biliary-Pancreatic and Liver Transplant Service, Hospital Universitario "Infanta Cristina", Badajoz, Spain
| | - A Nogales-Muñoz
- Department of General Surgery, Hospital Universitario "Virgen del Rocío"-"Virgen Macarena"/Instituto de Biomedicina de Sevilla (IBiS)/CSIC/Universidad de Sevilla, Sevilla, Spain
| | - A Gila-Bohórquez
- Department of General Surgery, Hospital Universitario "Virgen del Rocío"-"Virgen Macarena"/Instituto de Biomedicina de Sevilla (IBiS)/CSIC/Universidad de Sevilla, Sevilla, Spain
| | - D Pacheco
- Department of General Surgery and Department of Pathology, Hospital Universitario "Rio Hortega", Valladolid, Spain
| | - M A Torres-Nieto
- Department of Pathology, Hospital Universitario "Rio Hortega", Valladolid, Spain
| | - J Serrano-Díaz-Canedo
- Department of General Surgery, Hospital Universitario "Virgen del Rocío"-"Virgen Macarena"/Instituto de Biomedicina de Sevilla (IBiS)/CSIC/Universidad de Sevilla, Sevilla, Spain
| | - G Suárez-Artacho
- Department of General Surgery, Hospital Universitario "Virgen del Rocío"-"Virgen Macarena"/Instituto de Biomedicina de Sevilla (IBiS)/CSIC/Universidad de Sevilla, Sevilla, Spain
| | - C Bernal-Bellido
- Department of General Surgery, Hospital Universitario "Virgen del Rocío"-"Virgen Macarena"/Instituto de Biomedicina de Sevilla (IBiS)/CSIC/Universidad de Sevilla, Sevilla, Spain
| | - L M Marín-Gómez
- Department of General Surgery, Hospital Universitario "Virgen del Rocío"-"Virgen Macarena"/Instituto de Biomedicina de Sevilla (IBiS)/CSIC/Universidad de Sevilla, Sevilla, Spain
| | - J A Barcena
- Department of Biochemistry and Molecular Biology, University of Cordoba, Instituto Maimónides de Investigación Biomédica de Córdoba (IMIBIC), 14071, Córdoba, Spain
| | - M A Gómez-Bravo
- Department of General Surgery, Hospital Universitario "Virgen del Rocío"-"Virgen Macarena"/Instituto de Biomedicina de Sevilla (IBiS)/CSIC/Universidad de Sevilla, Sevilla, Spain; CENTRO DE INVESTIGACIÓN BIOMÉDICA EN RED de Enfermedades Hepáticas y Digestivas (CIBERehd), Spain
| | - C A Padilla
- Department of Biochemistry and Molecular Biology, University of Cordoba, Instituto Maimónides de Investigación Biomédica de Córdoba (IMIBIC), 14071, Córdoba, Spain
| | - F J Padillo
- Department of General Surgery, Hospital Universitario "Virgen del Rocío"-"Virgen Macarena"/Instituto de Biomedicina de Sevilla (IBiS)/CSIC/Universidad de Sevilla, Sevilla, Spain; CENTRO DE INVESTIGACIÓN BIOMÉDICA EN RED de Enfermedades Hepáticas y Digestivas (CIBERehd), Spain
| | - J Muntané
- Department of General Surgery, Hospital Universitario "Virgen del Rocío"-"Virgen Macarena"/Instituto de Biomedicina de Sevilla (IBiS)/CSIC/Universidad de Sevilla, Sevilla, Spain; CENTRO DE INVESTIGACIÓN BIOMÉDICA EN RED de Enfermedades Hepáticas y Digestivas (CIBERehd), Spain.
| |
Collapse
|
4
|
Serradilla-Martín M, Paterna-López S, Palomares-Cano A, Cantalejo-Díaz M, Abadía-Forcén T, Gutiérrez-Díez ML, Artigas-Marco C, Serrablo-Requejo A. Polyethylene glycol-coated haemostatic patch for prevention of clinically relevant postoperative pancreatic fistula after pancreatoduodenectomy: randomized clinical trial. BJS Open 2023; 7:7109454. [PMID: 37021546 PMCID: PMC10077024 DOI: 10.1093/bjsopen/zrad028] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Grants] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/01/2022] [Revised: 02/07/2023] [Accepted: 02/09/2023] [Indexed: 04/07/2023] Open
Abstract
BACKGROUND The potential of haemostatic patches to reduce the rate of postoperative pancreatic fistula remains unclear. The aim of this trial was to evaluate the impact of a polyethylene glycol-coated haemostatic patch on the incidence of clinically relevant postoperative pancreatic fistula after pancreatoduodenectomy. METHODS In this randomized, single-centre, clinical trial, patients undergoing pancreatoduodenectomy were randomized 1 : 1 to receive pancreatojejunostomy reinforced with two polyethylene glycol-coated haemostatic patches (patch group) or without any reinforcement (control group). The primary outcome was clinically relevant postoperative pancreatic fistula, defined as grade B/C according to International Study Group of Pancreatic Surgery criteria, within 90 days. Key secondary outcomes were length of hospital stay, total rate of postoperative pancreatic fistula, and overall complication rate. RESULTS From 15 May 2018 to 22 June 2020, 72 patients were randomized, and 64 were included in the analyses (31 in the patch group and 33 in the control group). The risk of clinically relevant postoperative pancreatic fistula was reduced by 90 per cent (OR 0.10, 95 per cent c.i. 0.01 to 0.89, P = 0.039). Moreover, the use of the polyethylene glycol-coated patch retained its protective effect on clinically relevant postoperative pancreatic fistula in a multivariable regression model, significantly reducing the risk of clinically relevant postoperative pancreatic fistula by 93 per cent (OR 0.07, 95 per cent c.i. 0.01 to 0.67, P = 0.021), regardless of patient age, sex, or fistula risk score. The incidence of secondary outcomes did not significantly differ between the groups. One patient died within 90 days in the patch group versus three patients in the control group. CONCLUSIONS A polyethylene glycol-coated haemostatic patch reduced the incidence of clinically relevant postoperative pancreatic fistula after pancreatoduodenectomy. REGISTRATION NUMBER NCT03419676 (http://www.clinicaltrials.gov).
Collapse
Affiliation(s)
- Mario Serradilla-Martín
- Department of Surgery, Instituto de Investigación Sanitaria Aragón, Miguel Servet University Hospital, Zaragoza, Spain
| | | | - Ana Palomares-Cano
- Department of Surgery, Miguel Servet University Hospital, Zaragoza, Spain
| | | | | | | | | | | |
Collapse
|
5
|
Blanco-Fernández G, Fondevila-Campo C, Sanjuanbenito A, Fabregat-Prous J, Secanella-Medayo L, Rotellar-Sastre F, Pardo-Sánchez F, Prieto-Calvo M, Marín-Ortega H, Sánchez-Cabús S, Diez-Valladares L, Alonso-Casado Ó, González-Serrano C, Rodríguez-Sanjuan JC, García-Plaza G, Jaén-Torrejimeno I, Suárez-Muñoz MÁ, Becerra-Massare A, Rio PSD, Pando E, López-Andújar R, Muñoz-Forner E, Rodriguez-López M, Pereira F, Serrablo-Requejo A, Turrión VS, Garrido MJ, Burdío F, Martín-Pérez E, Estevan-Estevan R, López-Guerra D, Castell-Gómez J, Salinas-Gómez J, López-Baena JÁ, López-Ben S, Solar-García L, Pérez-Alonso AJ, Martínez-Insfran LA, Blas JL, Cornejo M, Gutierrez-Calvo A, Pozo CDD, Ochando-Cerdan F, Muñoz-Bellvís L, Rebollar-Saenz J, Sánchez B, Jover JM, Gómez-Bravo MÁ, Ramia JM, Rojas-Holguín A. Pancreatic metastases from renal cell carcinoma. Postoperative outcome after surgical treatment in a Spanish multicenter study (PANMEKID). Eur J Surg Oncol 2022; 48:133-141. [PMID: 34417061 DOI: 10.1016/j.ejso.2021.08.011] [Citation(s) in RCA: 10] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/01/2021] [Revised: 07/17/2021] [Accepted: 08/09/2021] [Indexed: 02/07/2023]
Abstract
BACKGROUND Renal Cell Carcinoma (RCC) occasionally spreads to the pancreas. The purpose of our study is to evaluate the short and long-term results of a multicenter series in order to determine the effect of surgical treatment on the prognosis of these patients. METHODS Multicenter retrospective study of patients undergoing surgery for RCC pancreatic metastases, from January 2010 to May 2020. Variables related to the primary tumor, demographics, clinical characteristics of metastasis, location in the pancreas, type of pancreatic resection performed and data on short and long-term evolution after pancreatic resection were collected. RESULTS The study included 116 patients. The mean time between nephrectomy and pancreatic metastases' resection was 87.35 months (ICR: 1.51-332.55). Distal pancreatectomy was the most performed technique employed (50 %). Postoperative morbidity was observed in 60.9 % of cases (Clavien-Dindo greater than IIIa in 14 %). The median follow-up time was 43 months (13-78). Overall survival (OS) rates at 1, 3, and 5 years were 96 %, 88 %, and 83 %, respectively. The disease-free survival (DFS) rate at 1, 3, and 5 years was 73 %, 49 %, and 35 %, respectively. Significant prognostic factors of relapse were a disease free interval of less than 10 years (2.05 [1.13-3.72], p 0.02) and a history of previous extrapancreatic metastasis (2.44 [1.22-4.86], p 0.01). CONCLUSIONS Pancreatic resection if metastatic RCC is found in the pancreas is warranted to achieve higher overall survival and disease-free survival, even if extrapancreatic metastases were previously removed. The existence of intrapancreatic multifocal compromise does not always warrant the performance of a total pancreatectomy in order to improve survival.
Collapse
Affiliation(s)
- Gerardo Blanco-Fernández
- Department of HBP and Liver Transplant Surgery, Hospital Universitario de Badajoz, Badajoz, Spain.
| | | | | | - Joan Fabregat-Prous
- Department of Surgery, Hospital Universitario de Bellvitge, Hospitalet de Llobregat, Spain
| | - Luís Secanella-Medayo
- Department of Surgery, Hospital Universitario de Bellvitge, Hospitalet de Llobregat, Spain
| | | | | | | | | | | | | | | | | | | | - Gabriel García-Plaza
- Department of Surgery, Hospital Insular de Gran Canaria, Las Palmas de Gran Canaria, Spain
| | - Isabel Jaén-Torrejimeno
- Department of HBP and Liver Transplant Surgery, Hospital Universitario de Badajoz, Badajoz, Spain
| | | | | | | | - Elizabeth Pando
- Department of Hepato-pancreato-biliary and Transplant Surgery, Hospital Universitario Vall d'Hebron, Barcelona, Spain
| | - Rafael López-Andújar
- Department of Surgery, Hospital Universitario y Politécnico La Fe, Valencia, Spain
| | - Elena Muñoz-Forner
- Department of Surgery, Hospital Clínico Universitariode Valencia, Valencia, Spain
| | - Mario Rodriguez-López
- Department of Surgery, Hospital Clínico Universitario de Valladolid, Valladolid, Spain
| | - Fernando Pereira
- Department of Surgery, Hospital Universitario de Fuenlabrada, Fuenlabrada, Madrid, Spain
| | | | - Víctor Sánchez Turrión
- Department of Surgery, Hospital Universitario Puerta de Hierro, Majadahonda, Madrid, Spain
| | - Manuel Jiménez Garrido
- Department of Surgery, Hospital Universitario Puerta de Hierro, Majadahonda, Madrid, Spain
| | | | - Elena Martín-Pérez
- Department of Surgery, Hospital Universitario de La Princesa, Madrid, Spain
| | | | - Diego López-Guerra
- Department of HBP and Liver Transplant Surgery, Hospital Universitario de Badajoz, Badajoz, Spain
| | | | | | | | - Santiago López-Ben
- Department of Surgery, Hospital Universitari Dr Josep Trueta, Girona, Spain
| | - Lorena Solar-García
- Department of Surgery, Hospital Universitario Central de Asturias, Oviedo, Spain
| | | | | | - Juan Luis Blas
- Department of Surgery, Hospital Royo Villanova, Zaragoza, Spain
| | - Marian Cornejo
- Department of Surgery, Hospital Marina Baixa, Villajoyosa, Alicante, Spain
| | - Alberto Gutierrez-Calvo
- Department of Surgery Hospital Universitario Principe de Asturias. Alcalá de Henares, Madrid, Spain
| | | | | | - Luis Muñoz-Bellvís
- Department of Surgery, Complejo Asistencial Universitario de Salamanca, Salamanca, Spain
| | | | - Belinda Sánchez
- Department of Surgery, Hospital Regional de Málaga, Málaga, Spain
| | - José María Jover
- Department of Surgery, Hospital Universitario de Getafe, Getafe, Madrid, Spain
| | | | - José M Ramia
- Department of Surgery, Hospital General Universitario de Alicante, Alicante, Spain
| | - Adela Rojas-Holguín
- Department of HBP and Liver Transplant Surgery, Hospital Universitario de Badajoz, Badajoz, Spain
| |
Collapse
|
6
|
Ramia-Angel JM, Jaén-Torrejimeno I, Serrablo-Requejo A, Rodriguez-Laiz GP, López-Guerra D, Abadía-Forcen T, Alenda C, Serradilla-Martín M, Blanco-Fernandez G. Adenosquamous cancer of the pancreas: A multicenter retrospective study. Gastroenterol Hepatol 2021; 45:543-551. [PMID: 34952130 DOI: 10.1016/j.gastrohep.2021.12.006] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Received: 08/05/2021] [Revised: 12/09/2021] [Accepted: 12/16/2021] [Indexed: 11/28/2022]
Abstract
INTRODUCTION Adenosquamous cancer of the pancreas (ASCP) is an aggressive, infrequent subtype of pancreatic cancer that combines a glandular and squamous component and is associated with poor survival. METHODS Multicenter retrospective observational study carried out at three Spanish hospitals. The study period was: January 2010- August 2020. A descriptive analysis of the data was performed, as well as an analysis of global and disease-free survival using the Kaplan-Meier statistic. RESULTS Of a total of 668 pancreatic cancers treated surgically, twelve were ASCP (1.8%). Patient mean age was 69.2±7.4 years. Male/female ratio was 1:1. The main symptom was jaundice (seven patients). Correct preoperative diagnosis was obtained in only two patients. Nine pancreatoduodenectomies and three distal pancreatectosplenectomies were performed. 25% had major complications. Mean tumor size was 48.6±19.4 mm. Nine patients received adjuvant chemotherapy. Median survival time was 5.9 months, and median disease-free survival was 4.6 months. 90% of patients presented recurrence. Ten of the twelve patients in the study (83.3%) died, with disease progression being the cause in eight. Of the two surviving patients, one is disease-free and the other has liver metastases. CONCLUSION ASCP is a very rare pancreatic tumor with aggressive behavior. It is rarely diagnosed preoperatively. The best treatment, if feasible, is surgery followed by the standard chemotherapy regimens for pancreatic adenocarcinoma.
Collapse
Affiliation(s)
- Jose Manuel Ramia-Angel
- Servicio de Cirugía General. Hospital General Universitario, Alicante, España; ISABIAL: Instituto de Investigación Sanitaria y Biomédica, Alicante, España
| | | | - Alejandro Serrablo-Requejo
- Servicio de Cirugía General. Hospital Universitario Miguel Servet, Zaragoza, España; Instituto de Investigación Sanitaria de Aragón, Zaragoza, España
| | - Gonzalo P Rodriguez-Laiz
- Servicio de Cirugía General. Hospital General Universitario, Alicante, España; ISABIAL: Instituto de Investigación Sanitaria y Biomédica, Alicante, España
| | - Diego López-Guerra
- Servicio de Cirugía General. Complejo Hospitalario de Badajoz, Badajoz, España
| | - Teresa Abadía-Forcen
- Servicio de Cirugía General. Hospital Universitario Miguel Servet, Zaragoza, España
| | - Cristina Alenda
- Servicio de Cirugía General. Hospital General Universitario, Alicante, España; Servicio de Anatomía Patológica. Hospital General Universitario, Alicante, España
| | - Mario Serradilla-Martín
- Servicio de Cirugía General. Hospital Universitario Miguel Servet, Zaragoza, España; Instituto de Investigación Sanitaria de Aragón, Zaragoza, España.
| | - Gerardo Blanco-Fernandez
- Servicio de Cirugía General. Complejo Hospitalario de Badajoz, Badajoz, España; Universidad de Extremadura, Badajoz, España
| |
Collapse
|
7
|
Ramia JM, del Rio Martín J, Blanco-Fernández G, Cantalejo-Diaz M, Pardo F, Muñoz-Forner E, Carabias A, Manuel-Vazquez A, Hernández-Rivera PJ, Jaén-Torrejimeno I, Kälviäinen-Mejia HK, Rotellar-Sastre F, Garcés-Albir M, Latorre R, Longoria-Dubocq T, De Armas-Conde N, Serrablo-Requejo A, Gordillo SE, Sabater L, Serradilla-Martín M. Pancreatic mucinous cystic neoplasms located in the distal pancreas: a multicenter study. Gland Surg 2021; 11:795-804. [DOI: 10.21037/gs-21-703] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/17/2021] [Accepted: 03/29/2022] [Indexed: 11/06/2022]
|
8
|
Rodríguez-Hernández A, Navarro-Villarán E, González R, Pereira S, Soriano-De Castro LB, Sarrias-Giménez A, Barrera-Pulido L, Álamo-Martínez JM, Serrablo-Requejo A, Blanco-Fernández G, Nogales-Muñoz A, Gila-Bohórquez A, Pacheco D, Torres-Nieto MA, Serrano-Díaz-Canedo J, Suárez-Artacho G, Bernal-Bellido C, Marín-Gómez LM, Barcena JA, Gómez-Bravo MA, Padilla CA, Padillo FJ, Muntané J. Regulation of cell death receptor S-nitrosylation and apoptotic signaling by Sorafenib in hepatoblastoma cells. Redox Biol 2015; 6:174-182. [PMID: 26233703 PMCID: PMC4534573 DOI: 10.1016/j.redox.2015.07.010] [Citation(s) in RCA: 20] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/18/2015] [Revised: 07/17/2015] [Accepted: 07/20/2015] [Indexed: 12/15/2022] Open
Abstract
Nitric oxide (NO) plays a relevant role during cell death regulation in tumor cells. The overexpression of nitric oxide synthase type III (NOS-3) induces oxidative and nitrosative stress, p53 and cell death receptor expression and apoptosis in hepatoblastoma cells. S-nitrosylation of cell death receptor modulates apoptosis. Sorafenib is the unique recommended molecular-targeted drug for the treatment of patients with advanced hepatocellular carcinoma. The present study was addressed to elucidate the potential role of NO during Sorafenib-induced cell death in HepG2 cells. We determined the intra- and extracellular NO concentration, cell death receptor expression and their S-nitrosylation modifications, and apoptotic signaling in Sorafenib-treated HepG2 cells. The effect of NO donors on above parameters has also been determined. Sorafenib induced apoptosis in HepG2 cells. However, low concentration of the drug (10nM) increased cell death receptor expression, as well as caspase-8 and -9 activation, but without activation of downstream apoptotic markers. In contrast, Sorafenib (10 µM) reduced upstream apoptotic parameters but increased caspase-3 activation and DNA fragmentation in HepG2 cells. The shift of cell death signaling pathway was associated with a reduction of S-nitrosylation of cell death receptors in Sorafenib-treated cells. The administration of NO donors increased S-nitrosylation of cell death receptors and overall induction of cell death markers in control and Sorafenib-treated cells. In conclusion, Sorafenib induced alteration of cell death receptor S-nitrosylation status which may have a relevant repercussion on cell death signaling in hepatoblastoma cells.
Collapse
Affiliation(s)
- A Rodríguez-Hernández
- Institute of Biomedicine of Seville (IBiS), Hospital Universitario "Virgen del Rocío"/CSIC/Universidad de Sevilla, Av. Manuel Siurot s/n, 41013 Sevilla, Spain
| | - E Navarro-Villarán
- Institute of Biomedicine of Seville (IBiS), Hospital Universitario "Virgen del Rocío"/CSIC/Universidad de Sevilla, Av. Manuel Siurot s/n, 41013 Sevilla, Spain
| | - R González
- Departament of Biochemistry and Molecular Biology, University of Cordoba, Instituto Maimónides de Investigación Biomédica de Córdoba (IMIBIC), 14071 Córdoba, Spain
| | - S Pereira
- Institute of Biomedicine of Seville (IBiS), Hospital Universitario "Virgen del Rocío"/CSIC/Universidad de Sevilla, Av. Manuel Siurot s/n, 41013 Sevilla, Spain
| | - L B Soriano-De Castro
- Institute of Biomedicine of Seville (IBiS), Hospital Universitario "Virgen del Rocío"/CSIC/Universidad de Sevilla, Av. Manuel Siurot s/n, 41013 Sevilla, Spain
| | - A Sarrias-Giménez
- Institute of Biomedicine of Seville (IBiS), Hospital Universitario "Virgen del Rocío"/CSIC/Universidad de Sevilla, Av. Manuel Siurot s/n, 41013 Sevilla, Spain
| | - L Barrera-Pulido
- Department of General Surgery, Hospital Universitario "Virgen del Rocío" - "Virgen Macarena"/Instituto de Biomedicina de Sevilla (IBiS)/CSIC/Universidad de Sevilla, Sevilla, Spain
| | - J M Álamo-Martínez
- Department of General Surgery, Hospital Universitario "Virgen del Rocío" - "Virgen Macarena"/Instituto de Biomedicina de Sevilla (IBiS)/CSIC/Universidad de Sevilla, Sevilla, Spain; CENTRO DE INVESTIGACIÓN BIOMÉDICA EN RED de Enfermedades Hepáticas y Digestivas (CIBERehd), Spain
| | - A Serrablo-Requejo
- Hepato-Biliary Surgery Unit, Hospital Universitario "Miguel Servet", Zaragoza, Spain
| | - G Blanco-Fernández
- Hepato-Biliary-Pancreatic and Liver Transplant Service, Hospital Universitario "Infanta Cristina", Badajoz, Spain
| | - A Nogales-Muñoz
- Department of General Surgery, Hospital Universitario "Virgen del Rocío" - "Virgen Macarena"/Instituto de Biomedicina de Sevilla (IBiS)/CSIC/Universidad de Sevilla, Sevilla, Spain
| | - A Gila-Bohórquez
- Department of General Surgery, Hospital Universitario "Virgen del Rocío" - "Virgen Macarena"/Instituto de Biomedicina de Sevilla (IBiS)/CSIC/Universidad de Sevilla, Sevilla, Spain
| | - D Pacheco
- Department of General Surgery and Department of Pathology, Hospital Universitario "Rio Hortega", Valladolid, Spain
| | - M A Torres-Nieto
- Department of Pathology, Hospital Universitario "Rio Hortega", Valladolid, Spain
| | - J Serrano-Díaz-Canedo
- Department of General Surgery, Hospital Universitario "Virgen del Rocío" - "Virgen Macarena"/Instituto de Biomedicina de Sevilla (IBiS)/CSIC/Universidad de Sevilla, Sevilla, Spain
| | - G Suárez-Artacho
- Department of General Surgery, Hospital Universitario "Virgen del Rocío" - "Virgen Macarena"/Instituto de Biomedicina de Sevilla (IBiS)/CSIC/Universidad de Sevilla, Sevilla, Spain
| | - C Bernal-Bellido
- Department of General Surgery, Hospital Universitario "Virgen del Rocío" - "Virgen Macarena"/Instituto de Biomedicina de Sevilla (IBiS)/CSIC/Universidad de Sevilla, Sevilla, Spain
| | - L M Marín-Gómez
- Department of General Surgery, Hospital Universitario "Virgen del Rocío" - "Virgen Macarena"/Instituto de Biomedicina de Sevilla (IBiS)/CSIC/Universidad de Sevilla, Sevilla, Spain
| | - J A Barcena
- Departament of Biochemistry and Molecular Biology, University of Cordoba, Instituto Maimónides de Investigación Biomédica de Córdoba (IMIBIC), 14071 Córdoba, Spain
| | - M A Gómez-Bravo
- Department of General Surgery, Hospital Universitario "Virgen del Rocío" - "Virgen Macarena"/Instituto de Biomedicina de Sevilla (IBiS)/CSIC/Universidad de Sevilla, Sevilla, Spain; CENTRO DE INVESTIGACIÓN BIOMÉDICA EN RED de Enfermedades Hepáticas y Digestivas (CIBERehd), Spain
| | - C A Padilla
- Departament of Biochemistry and Molecular Biology, University of Cordoba, Instituto Maimónides de Investigación Biomédica de Córdoba (IMIBIC), 14071 Córdoba, Spain
| | - F J Padillo
- Department of General Surgery, Hospital Universitario "Virgen del Rocío" - "Virgen Macarena"/Instituto de Biomedicina de Sevilla (IBiS)/CSIC/Universidad de Sevilla, Sevilla, Spain; CENTRO DE INVESTIGACIÓN BIOMÉDICA EN RED de Enfermedades Hepáticas y Digestivas (CIBERehd), Spain
| | - J Muntané
- Department of General Surgery, Hospital Universitario "Virgen del Rocío" - "Virgen Macarena"/Instituto de Biomedicina de Sevilla (IBiS)/CSIC/Universidad de Sevilla, Sevilla, Spain; CENTRO DE INVESTIGACIÓN BIOMÉDICA EN RED de Enfermedades Hepáticas y Digestivas (CIBERehd), Spain.
| |
Collapse
|
9
|
Serrablo-Requejo A, Paterna-López S, Cerdán R, Esarte-Muniaín J. La morbilidad y la transfusión: homogeneizar las series. Cir Esp 2005; 78:392. [PMID: 16420871 DOI: 10.1016/s0009-739x(05)70963-5] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022]
|